DK3105253T3 - Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse - Google Patents

Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3105253T3
DK3105253T3 DK15706124.3T DK15706124T DK3105253T3 DK 3105253 T3 DK3105253 T3 DK 3105253T3 DK 15706124 T DK15706124 T DK 15706124T DK 3105253 T3 DK3105253 T3 DK 3105253T3
Authority
DK
Denmark
Prior art keywords
seq
amino acid
antibody
acid sequence
gly
Prior art date
Application number
DK15706124.3T
Other languages
English (en)
Inventor
Yvonne Chinn
Julie Q Hang
Christian W Siebel
Yan Wu
Daniel Lafkas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52574459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3105253(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3105253T3 publication Critical patent/DK3105253T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (31)

1. Isoleret antistof, der binder sig til humant Jaggedl, hvor antistoffet omfatter en HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 35 eller 78, en HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28 eller 36, en HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 55 eller 59, hvor X er en hvilken som helst anden aminosyre end S eller H, en HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, en HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og en HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16 eller 40.
2. Isoleret antistof ifølge krav 1, hvor antistoffet omfatter: a) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 55, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 40; eller b) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 59, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller c) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 59, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16.
3. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet omfatter: a) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 54, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 34; eller b) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 58, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 10; eller c) en VH-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 62, og en VL-sekvens, der stemmer mindst 95 % overens med aminosyresekvensen ifølge SEQ ID NO: 26; eller d) en VH-sekvens ifølge SEQ ID NO: 54 og en VL-sekvens ifølge SEQ ID NO: 34; eller e) en VH-sekvens ifølge SEQ ID NO: 58 og en VL-sekvens ifølge SEQ ID NO: 10; eller f) en VH-sekvens ifølge SEQ ID NO: 62 og en VL-sekvens ifølge SEQ ID NO: 26.
4. Isoleret antistof ifølge krav 3, hvor antistoffet omfatter en VH-sekvens ifølge SEQ ID NO: 54 og en VL-sekvens ifølge SEQ ID NO: 34.
5. Isoleret antistof ifølge krav 4, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 56 eller SEQ ID NO: 57, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
6. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor X er valgt blandt A, D, E, G, I, K, L, N, Q, R, T og V.
7. Isoleret antistof ifølge et hvilket som helst af de foregående krav, hvor X er T.
8. Isoleret antistof ifølge et hvilket som helst af de foregående krav, omfattende: a) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 37, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 40; eller b) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 36, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 64, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller c) HVR-H1 omfattende aminosyresekvensen ifølge SEQ ID NO: 78, HVR-H2 omfattende aminosyresekvensen ifølge SEQ ID NO: 28, HVR-H3 omfattende aminosyresekvensen ifølge SEQ ID NO: 64, HVR-L1 omfattende aminosyresekvensen ifølge SEQ ID NO: 38, HVR-L2 omfattende aminosyresekvensen ifølge SEQ ID NO: 39 og HVR-L3 omfattende aminosyresekvensen ifølge SEQ ID NO: 16; eller d) en VH-sekvens ifølge SEQ ID NO: 33 og en VL-sekvens ifølge SEQ ID NO: 34; eller e) en VH-sekvens ifølge SEQ ID NO: 65 og en VL-sekvens ifølge SEQ ID NO: 10; eller f) en VH-sekvens ifølge SEQ ID NO: 66 og en VL-sekvens ifølge SEQ ID NO: 26.
9. Isoleret antistof ifølge krav 8, hvor antistoffet omfatter en VH-sekvens ifølge SEQ ID NO: 33 og en VL-sekvens ifølge SEQ ID NO: 34.
10. Antistof ifølge et hvilket som helst af de foregående krav, der er et IgGl-antistof i fuld længde.
11. Antistof ifølge krav 10, hvor antistoffet i det væsentlige mangler en effektorfunktion.
12. Antistof ifølge krav 10 hvor tungkæden omfatter en N297G- eller N297A-mutation.
13. Isoleret antistof ifølge krav 8, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 51, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
14. Isoleret antistof ifølge krav 8, hvor tungkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 52, og letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 53.
15. Antistof ifølge krav 8, hvor antistoffet omfatter: a) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 69 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 75; eller b) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 70 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 76; eller c) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 79 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 75; eller d) en tungkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 80 og en letkæde omfattende aminosyresekvensen ifølge SEQ ID NO: 76.
16. Antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet er en antagonist for Jaggedl-medieret signalering.
17. Antistof ifølge et hvilket som helst af de foregående krav, hvor antistoffet ikke binder sig til humant Jagged2, og/eller hvor antistoffet ikke binder sig til humant DLL4, og/eller hvor antistoffet ikke binder sig til humant DLL1, og/eller hvor antistoffet ikke binder sig til murint Jagged2, murint DLL4 og/eller murint DLL1.
18. Isoleret nukleinsyre, der koder for antistoffet ifølge et hvilket som helst af de foregående krav.
19. Værtscelle, der omfatter den isolerede nukleinsyre ifølge krav 18.
20. Fremgangsmåde til fremstilling af et antistof, der omfatter dyrkning af værtscellen ifølge krav 19, således at antistoffet fremstilles.
21. Immunkonjugat, der omfatter antistoffet ifølge et hvilket som helst af kravene 1 til 17 og et cytotoksisk middel.
22. Farmaceutisk formulering, der omfattende antistoffet ifølge et hvilket som helst af kravene 1 til 17 og en farmaceutisk acceptabel bærer.
23. Antistof ifølge et hvilket som helst af kravene 1 til 17 eller immunkonjugat ifølge krav 21 til anvendelse som medikament.
24. Antistof ifølge et hvilket som helst af kravene 1 til 17 eller immunkonjugat ifølge krav 21 til anvendelse ved behandling afkræft.
25. Antistof ifølge et hvilket som helst af kravene 1 til 17 til anvendelse ved behandling af allergi, astma, autoimmun sygdom, sygdomme forbundet med bægercellemetaplasi (for eksempel i lungerne) og/eller overskydende slim.
26. Antistof til anvendelse ifølge krav 25 til anvendelse ved behandling en sygdom forbundet med bægercellemetaplasi.
27. Antistof til anvendelse ifølge krav 26 til anvendelse ved behandling af astma, cystisk fibrose, kronisk obstruktiv lungesygdom eller Barretts øsofagus.
28. Antistof til anvendelse ifølge krav 24, hvor kræften er udvalgt blandt brystkræft, lungekræft, hjernekræft, livmoderhalskræft, tyktarmskræft, leverkræft, galdegangskræft, bugspytkirtelkræft, hudkræft samt B-celle- og T-celle-maligniteter.
29. Isoleret antistof ifølge et hvilket som helst af kravene 1 til 17 konjugeret til en markør.
30. Isoleret antistof ifølge krav 29, hvor markøren er en positronemitter, fortrinsvis hvor positronemitteren er 89Zr.
31. Fremgangsmåde til påvisning af humant Jaggedl i en biologisk prøve, der omfatter at bringe den biologiske prøve i kontakt med antistoffet ifølge et hvilket som helst af kravene 1 til 17, 29 og 30 under betingelser, der tillader binding af antistoffet til et naturligt forekommende humant Jaggedl, og at påvise om et kompleks dannes mellem antistoffet og et naturligt forekommende humant Jaggedl i den biologiske prøve.
DK15706124.3T 2014-02-12 2015-02-11 Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse DK3105253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939110P 2014-02-12 2014-02-12
PCT/US2015/015456 WO2015123325A1 (en) 2014-02-12 2015-02-11 Anti-jagged1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
DK3105253T3 true DK3105253T3 (da) 2018-09-03

Family

ID=52574459

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15706124.3T DK3105253T3 (da) 2014-02-12 2015-02-11 Anti-Jagged1-antistoffer og fremgangsmåder til anvendelse

Country Status (33)

Country Link
US (5) US9518121B2 (da)
EP (3) EP3105253B1 (da)
JP (1) JP6571115B2 (da)
KR (2) KR102030891B1 (da)
CN (2) CN106068277B (da)
AR (1) AR099465A1 (da)
AU (3) AU2015217271B2 (da)
BR (1) BR112016017986A2 (da)
CA (2) CA2936565C (da)
CL (1) CL2016002004A1 (da)
CR (1) CR20160362A (da)
DK (1) DK3105253T3 (da)
EA (1) EA201691610A8 (da)
ES (1) ES2685424T3 (da)
HR (1) HRP20181359T1 (da)
HU (1) HUE039940T2 (da)
IL (1) IL246736B (da)
LT (1) LT3105253T (da)
MA (1) MA39248B1 (da)
MX (1) MX372675B (da)
MY (1) MY176855A (da)
PE (1) PE20161335A1 (da)
PH (2) PH12016501435A1 (da)
PL (1) PL3105253T3 (da)
PT (1) PT3105253T (da)
RS (1) RS57608B1 (da)
SG (2) SG11201606607UA (da)
SI (1) SI3105253T1 (da)
TR (1) TR201810635T4 (da)
TW (2) TWI631135B (da)
UA (1) UA121464C2 (da)
WO (1) WO2015123325A1 (da)
ZA (1) ZA201800315B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
BR112015003032B1 (pt) 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
SG11201507427QA (en) 2013-03-15 2015-10-29 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EA201691610A8 (ru) 2014-02-12 2018-05-31 Дженентек, Инк. Анти-jagged1 антитела и способы применения
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
MA40589A (fr) * 2014-08-22 2017-06-28 Procella Therapeutics Ab Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
DK3417073T3 (da) 2016-02-19 2023-10-30 Procella Therapeutics Ab Genetiske markører til transplantation af humane, hjerteventrikulære progenitorceller
WO2017205651A1 (en) * 2016-05-25 2017-11-30 The Trustees Of Columbia University In The City Of New York Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
WO2019036613A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
WO2019038587A1 (en) 2017-08-23 2019-02-28 Procella Therapeutics Ab USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS
WO2019152599A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
CA2496547A1 (en) 2002-08-29 2004-03-11 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP2007512348A (ja) 2003-11-26 2007-05-17 ヘルス　リサーチ　インコーポレイテッド 形質細胞の治療のためのノッチ経路干渉剤の使用
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (da) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antistoffer og konjugater
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE602005022928D1 (de) * 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007058987A1 (en) * 2005-11-10 2007-05-24 Bristol-Myers Squibb Company Methods of identifying compounds that inhibit notch cleavage
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
BRPI0706840A2 (pt) * 2006-01-05 2011-04-05 Genentech Inc anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20080226645A1 (en) * 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
WO2008109773A2 (en) * 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
EP2155249A4 (en) * 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP2011516520A (ja) * 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
AR073717A1 (es) 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
MX342250B (es) * 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
WO2011063237A2 (en) * 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20130309246A1 (en) 2011-02-02 2013-11-21 The Trustees Of Princeton University Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
EP2863948B1 (en) * 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
BR112015003032B1 (pt) * 2012-08-13 2023-03-28 Genentech, Inc Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo
GB201300706D0 (en) * 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
SG11201507427QA (en) 2013-03-15 2015-10-29 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
EA201691610A8 (ru) 2014-02-12 2018-05-31 Дженентек, Инк. Анти-jagged1 антитела и способы применения
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Also Published As

Publication number Publication date
US20170137531A1 (en) 2017-05-18
US20150252117A1 (en) 2015-09-10
US20240384000A1 (en) 2024-11-21
TW201613963A (en) 2016-04-16
AU2018229549A1 (en) 2018-10-04
KR20190114046A (ko) 2019-10-08
LT3105253T (lt) 2018-09-10
CA2936565A1 (en) 2015-08-20
WO2015123325A1 (en) 2015-08-20
MA39248B1 (fr) 2018-10-31
CN106068277A (zh) 2016-11-02
AU2015217271B2 (en) 2018-10-25
CN111499741A (zh) 2020-08-07
US9518121B2 (en) 2016-12-13
PE20161335A1 (es) 2016-12-07
CN106068277B (zh) 2021-08-24
JP2017512067A (ja) 2017-05-18
TWI631135B (zh) 2018-08-01
RS57608B1 (sr) 2018-11-30
PL3105253T3 (pl) 2018-12-31
UA121464C2 (uk) 2020-06-10
PH12020550781A1 (en) 2021-08-02
SI3105253T1 (sl) 2018-10-30
EP3825332A1 (en) 2021-05-26
IL246736B (en) 2020-09-30
US11926674B2 (en) 2024-03-12
TR201810635T4 (tr) 2018-08-27
ZA201800315B (en) 2020-05-27
CA2936565C (en) 2020-08-11
EA201691610A8 (ru) 2018-05-31
CL2016002004A1 (es) 2017-01-20
MX2016010433A (es) 2016-09-22
AU2020203547A1 (en) 2020-06-18
KR20160118348A (ko) 2016-10-11
PT3105253T (pt) 2018-10-04
CA3045124A1 (en) 2015-08-20
HRP20181359T1 (hr) 2018-10-19
TW201902515A (zh) 2019-01-16
US20210206871A1 (en) 2021-07-08
IL246736A0 (en) 2016-08-31
PH12016501435A1 (en) 2017-02-06
US10011661B2 (en) 2018-07-03
KR102030891B1 (ko) 2019-10-11
MX372675B (es) 2020-03-25
MY176855A (en) 2020-08-24
CR20160362A (es) 2016-09-20
EP3105253B1 (en) 2018-06-27
HUE039940T2 (hu) 2019-02-28
EA201691610A1 (ru) 2016-11-30
US20180371098A1 (en) 2018-12-27
JP6571115B2 (ja) 2019-09-04
SG11201606607UA (en) 2016-09-29
US10858440B2 (en) 2020-12-08
EP3105253A1 (en) 2016-12-21
ES2685424T3 (es) 2018-10-09
EP3428190A1 (en) 2019-01-16
AU2015217271A1 (en) 2016-08-11
AR099465A1 (es) 2016-07-27
SG10201808259TA (en) 2018-10-30
BR112016017986A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
US20240384000A1 (en) Anti-Jagged1 Antibodies and Methods of Use
US20240034805A1 (en) Anti-Jagged Antibodies and Methods of Use
HK1227041B (zh) 抗锯齿蛋白1抗体及使用方法
HK1227041A1 (en) Anti-jagged1 antibodies and methods of use
HK1209432B (zh) 抗锯齿蛋白抗体及使用方法